We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
-13.86%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$310M
AUM Growth
-$124M
Cap. Flow
-$12.5M
Cap. Flow %
-4.04%
Top 10 Hldgs %
68.81%
Holding
86
New
8
Increased
20
Reduced
4
Closed
13

Top Buys

Rank Stock Value
1
TQQQ icon
ProShares UltraPro QQQ
TQQQ
+$13.3M
2
CVEO icon
Civeo
CVEO
+$8.13M
3
HLLY icon
Holley
HLLY
+$6.53M
4
CMPS
Compass Pathways
CMPS
+$3.74M
5
NN icon
NextNav
NN
+$2.4M

Top Sells

Rank Stock Value
1
KVYO icon
Klaviyo
KVYO
+$44.5M
2
SLRN
ACELYRIN
SLRN
+$8.74M
3
MREO
Mereo BioPharma
MREO
+$2.35M
4
PVLA
Palvella Therapeutics
PVLA
+$2.12M
5
GOCO
GoHealth
GOCO
+$888K

Sector Composition

Rank Sector Weight
1 Healthcare 44.2%
2 Financials 32.56%
3 Technology 12.36%
4 Consumer Discretionary 6.99%
5 Energy 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NCDL icon
1
Nuveen Churchill Direct Lending
NCDL
$602M
$68.6M 22.12%
4,039,553
– –
OBDC icon
2
Blue Owl Capital
OBDC
$5.36B
$30M 9.67%
2,045,070
– –
CGEM icon
3
Cullinan Oncology
CGEM
$1.08B
$18.4M 5.95%
2,435,972
+65,000
+3% +$624K
EVCM icon
4
EverCommerce
EVCM
$2.15B
$16.6M 5.34%
1,641,929
– –
TRML
5
DELISTED
Tourmaline Bio
TRML
$15.8M 5.09%
1,037,107
-42,214
-4% -$677K
CNDT icon
6
Conduent
CNDT
$245M
$15.4M 4.96%
5,697,450
+71,991
+1% +$263K
ENGN icon
7
enGene Therapeutics
ENGN
$118M
$14.7M 4.74%
3,279,378
+119,403
+4% +$742K
HLLY icon
8
Holley
HLLY
$326M
$13.7M 4.41%
5,318,040
+2,327,746
+78% +$6.53M
LRMR icon
9
Larimar Therapeutics
LRMR
$397M
$10.3M 3.31%
4,778,040
+125,000
+3% +$395K
TQQQ icon
10
ProShares UltraPro QQQ
TQQQ
$31.4B
$10M 3.23%
+350,000
New +$13.3M
CVEO icon
11
Civeo
CVEO
$350M
$8.01M 2.58%
+348,226
New +$8.13M
IRON icon
12
Disc Medicine
IRON
$3.03B
$6.96M 2.25%
140,260
+20,000
+17% +$1.11M
ELDN icon
13
Eledon Pharmaceuticals
ELDN
$263M
$6.17M 1.99%
1,819,912
-140,000
-7% -$576K
CMPX icon
14
Compass Therapeutics
CMPX
$349M
$5.61M 1.81%
2,954,712
– –
RARE icon
15
Ultragenyx Pharmaceutical
RARE
$2.56B
$5.55M 1.79%
153,238
+35,000
+30% +$1.46M
IMA
16
ImageneBio Inc
IMA
$67.2M
$5.24M 1.69%
340,927
– –
CNTA
17
DELISTED
Centessa Pharmaceuticals
CNTA
$4.53M 1.46%
315,000
+95,000
+43% +$1.55M
CNTX icon
18
Context Therapeutics
CNTX
$55.8M
$4.51M 1.45%
7,367,906
+1,009,978
+16% +$879K
SGMT icon
19
Sagimet Biosciences
SGMT
$451M
$4.33M 1.4%
1,328,351
+4,474
+0.3% +$18.8K
EYPT icon
20
EyePoint Inc
EYPT
$1.08B
$4.32M 1.39%
797,594
+130,000
+19% +$910K
PLRX icon
21
Pliant Therapeutics
PLRX
$65.6M
$4.01M 1.29%
2,969,199
+200,000
+7% +$1.21M
PVLA
22
Palvella Therapeutics
PVLA
$2.15B
$3.93M 1.27%
140,259
-109,803
-44% -$2.12M
RPTX
23
DELISTED
Repare Therapeutics
RPTX
$3.4M 1.09%
3,443,659
– –
ETWO
24
DELISTED
E2open Parent Holdings
ETWO
$3.3M 1.06%
1,650,943
– –
MLYS icon
25
Mineralys Therapeutics
MLYS
$2.31B
$3.28M 1.06%
+206,296
New +$2.37M
1
2 3 4

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $372M AUM 50.62% 1-Year Est. Return
AWA
Acumen Wealth Advisors Chattanooga, Tennessee $372M AUM
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return

Blue Owl Capital Holdings's Q1 2025 Portfolio in Review

As of Q1 2025, Blue Owl Capital Holdings held 86 positions worth $310M, down 29% from $434M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Blue Owl Capital Holdings withdrew a net $12.5M in Q1 2025, closing 13 positions and reducing 4 holdings. Its most notable exit was Klaviyo, an estimated $44.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 51% a quarter earlier, followed by Financials and Technology.

Against the trend, Blue Owl Capital Holdings opened a new position in ProShares UltraPro QQQ worth $10M.

  • Blue Owl Capital Holdings's largest Q1 2025 buy was ProShares UltraPro QQQ: 350,000 shares worth $10M.
  • Blue Owl Capital Holdings added most to Holley in Q1 2025, an estimated $6.53M increase.
  • Blue Owl Capital Holdings's biggest Q1 2025 reduction was Palvella Therapeutics, cutting an estimated $2.12M.
  • Blue Owl Capital Holdings fully exited Klaviyo in Q1 2025, selling an estimated $44.5M.
  • Blue Owl Capital Holdings's ten largest holdings make up 69% of its $310M portfolio in Q1 2025.
  • Blue Owl Capital Holdings opened 8 new positions and closed 13 in Q1 2025.
  • Blue Owl Capital Holdings's portfolio value fell 29% quarter-over-quarter to $310M.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2025, filed 15 May 2025.